Clinical Trial Update: A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia

View source ↗

Summary

A prospective non-interventional study in Russia evaluates clinical outcomes of Ribociclib (Risarg) combined with endocrine therapy or chemotherapy in HR-positi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Ribociclib (ribociclib)
• Risarg

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: HR+HER2- Advanced Breast Cancer | Status: ACTIVE_NOT_RECRUITING